Key Takeaways
- The ml volume you inject is not the dose: the dose is in micrograms (mcg), and the ml is calculated from your vial's reconstitution concentration.
- A 3 mg vial reconstituted with 3 ml of bacteriostatic water yields 1,000 mcg/ml; a common 300 mcg starting dose equals exactly 0.30 ml (30 units on a U-100 syringe).
- Sermorelin's half-life is roughly 10 to 20 minutes in circulation, which is why once-nightly bedtime dosing is used to mimic the natural pulsatile GH release.
- Geref (brand sermorelin) was withdrawn from the US market in 2008 for commercial reasons; all current US sermorelin is compounded and requires a valid prescription.
- No published RCT in healthy adults establishes an optimal mcg dose for body composition; most dose recommendations come from clinical experience and older pediatric GHD data.
Direct Answer: How Many ml of Sermorelin Should I Take?
Table of Contents
- Why "how many ml" is actually the wrong first question
- Reconstitution math: the calculation every user must know
- What dose range do clinicians actually use?
- How does sermorelin work and what do numbers show?
- Evidence ledger: what the research actually supports
- What most dosing pages get wrong
- Honest head-to-head: sermorelin vs tesamorelin vs CJC-1295
- Operational guide: reading your vial label and COA
- Stability and the degraded-vial problem
- FAQ
- Sources
Why "How Many ml" Is Actually the Wrong First Question
Milliliters measure volume, not biological activity. Two vials labeled "sermorelin" can have completely different concentrations depending on how much bacteriostatic water was added during reconstitution. A 3 mg vial reconstituted with 1 ml is three times as concentrated as the same vial reconstituted with 3 ml. Asking "how many ml" without knowing the concentration is like asking how many sips of a drink you need without knowing its strength.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The correct sequence is: (1) confirm your prescribed dose in mcg, (2) know the total peptide mass in your vial in mcg, (3) know how many ml of bacteriostatic water you added, (4) calculate the concentration, and (5) divide your dose by the concentration to get the volume to inject. Every step matters.
Reconstitution Math: The Calculation Every User Must Know
The formula is simple:
Volume to inject (ml) = Prescribed dose (mcg) / Concentration (mcg/ml)
Concentration (mcg/ml) = Total peptide in vial (mcg) / ml of bacteriostatic water added
| Vial size | BAC water added | Concentration | 300 mcg dose = | On U-100 syringe |
|---|---|---|---|---|
| 3 mg (3,000 mcg) | 1 ml | 3,000 mcg/ml | 0.10 ml | 10 units |
| 3 mg (3,000 mcg) | 2 ml | 1,500 mcg/ml | 0.20 ml | 20 units |
| 3 mg (3,000 mcg) | 3 ml | 1,000 mcg/ml | 0.30 ml | 30 units |
| 6 mg (6,000 mcg) | 3 ml | 2,000 mcg/ml | 0.15 ml | 15 units |
| 9 mg (9,000 mcg) | 3 ml | 3,000 mcg/ml | 0.10 ml | 10 units |
Why U-100 insulin syringes? Each unit mark equals 0.01 ml, giving 1% ml precision in a small, low dead-space syringe. U-40 syringes (40 units per ml) have different unit-to-ml ratios and should not be substituted without recalculating.
Important note on compounded vials: Your pharmacy may label the vial in mg or mcg. Convert: 1 mg equals 1,000 mcg. Always confirm units before calculating.
What Dose Range Do Clinicians Actually Use?
There is no FDA-approved adult dosing indication for compounded sermorelin. The former Geref Diagnostic product used 1 mcg/kg IV as a single diagnostic stimulus, a very different context from ongoing subcutaneous therapy. Current compounded sermorelin prescribing patterns in the US generally reflect the following ranges, based on clinical consensus rather than large RCT data:
| Purpose | Common starting dose | Common maintenance dose | Evidence basis |
|---|---|---|---|
| Adult GH optimization (clinical) | 200 to 300 mcg nightly SQ | 300 to 500 mcg nightly SQ | Clinical experience, weak observational data |
| Pediatric GHD (historical Geref) | 30 mcg/kg/day SQ (approved use) | Titrated by IGF-1 | FDA-approved labeling (withdrawn 2008) |
| Diagnostic test (Geref Diagnostic) | 1 mcg/kg IV single dose | Not applicable | Former FDA-approved indication |
Dose adjustments in adults are typically guided by serum IGF-1 levels drawn 4 to 8 weeks after starting therapy. Titration based on labs is more evidence-informed than fixed-dose escalation.
How Does Sermorelin Work and What Do the Numbers Show?
Sermorelin is a 29-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH), representing the first 29 residues of the native 44-amino-acid peptide. The N-terminal 29 residues retain full receptor-binding activity at the pituitary GHRH receptor (GHRHR), a G-protein-coupled receptor. Binding activates adenylyl cyclase, raises intracellular cAMP, and stimulates GH synthesis and release from somatotroph cells.
The plasma half-life is approximately 10 to 20 minutes (referenced in the former Geref prescribing information), which is shorter than tesamorelin (~26 minutes) and far shorter than DAC-CJC-1295 (days). This short half-life is why the pulsatile bedtime dosing strategy is used: the drug is cleared before the next natural pulse, preserving physiologic feedback architecture rather than creating continuous elevation.
What the mechanism does NOT prove: Pituitary stimulation producing more GH does not automatically translate to meaningful body composition change, anti-aging outcomes, or performance gains in adults with normal GH axes. The downstream IGF-1 elevation is real but modest in most adult users, and no large RCT has demonstrated clinically meaningful body composition endpoints specifically for sermorelin in healthy adults.
Evidence Ledger: What the Research Actually Supports
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| Sermorelin stimulates pituitary GH release | Human RCT (pediatric GHD), mechanistic studies | Positive, dose-dependent | High |
| Sermorelin raises serum IGF-1 in GH-deficient adults | Small human trials, case series | Positive | Moderate |
| Sermorelin improves body composition in healthy adults | No robust RCT; extrapolation from GH analog studies | Uncertain | Very low |
| Once-nightly SQ dosing is the optimal schedule | Pharmacokinetic rationale, clinical consensus | Directionally supported | Low (no head-to-head schedule trials) |
| 300 to 500 mcg is the optimal adult dose | Clinical experience, no dose-finding RCT in adults | Uncertain | Very low |
| Reconstituted sermorelin stable 30 days at 2 to 8 C | Compounding pharmacy labeling standards; no independent published kinetics found | Directionally plausible | Low |
| Injection site reactions (redness, swelling) occur | Former Geref prescribing information | Positive (adverse effect) | High |
What Most Dosing Pages Get Wrong
They give ml numbers without the concentration assumption. A page that says "inject 0.3 ml of sermorelin" is only correct if your vial happens to be 1,000 mcg/ml. If your pharmacy reconstituted differently, that number is wrong. The ml figure is meaningless without the concentration.
They treat all compounded sermorelin as equivalent. Compounding pharmacy quality varies. A vial labeled "3 mg sermorelin" should be tested for identity, potency, sterility, and endotoxins under USP 797 standards. A certificate of analysis (COA) from a third-party lab is the only way to verify what is actually in the vial. Most consumer-facing peptide guides never mention COA review.
They ignore the somatostatin rebound problem. Chronic supraphysiologic stimulation of somatotrophs can trigger compensatory somatostatin release, blunting the GH response over time. This is a documented phenomenon with GHRH analogs and is the pharmacological argument for cycling protocols or conservative dosing, not just stacking higher doses.
They confuse the diagnostic test dose with the therapy dose. The 1 mcg/kg IV figure from Geref Diagnostic is a single-use pituitary stimulation test, not a therapeutic protocol. It is cited out of context on many sites as if it anchors subcutaneous maintenance dosing.
Honest Head-to-Head: Sermorelin vs Tesamorelin vs CJC-1295 With DAC
| Feature | Sermorelin | Tesamorelin | CJC-1295 with DAC |
|---|---|---|---|
| Mechanism | GHRH receptor agonist (29 aa) | GHRH receptor agonist (44 aa analogue) | GHRH receptor agonist with albumin-binding DAC |
| Half-life | ~10 to 20 minutes | ~26 minutes | Days (albumin-bound) |
| GH pulse profile | Pulsatile (physiologic) | Pulsatile | Sustained elevation (non-physiologic) |
| FDA status (US) | No current approval; compounded only | FDA-approved (Egrifta, HIV lipodystrophy) | No approval; research/compounded only |
| Strongest evidence base | Pediatric GHD (withdrawn indication) | Adult HIV-lipodystrophy RCTs | Animal and small human studies |
| Where sermorelin LOSES | Weaker evidence in adults vs tesamorelin | Better evidence; approved indication | Longer dosing interval (convenience) |
| Where sermorelin wins or ties | Most physiologic pulse profile; lower cost per vial vs tesamorelin brand | Sermorelin cheaper | Sermorelin has more safety history |
| Injection frequency | Daily (nightly) | Daily (nightly) | 1 to 2 times weekly |
If you are choosing between these agents, tesamorelin has the strongest published evidence in adults by a wide margin due to its FDA approval pathway and supporting RCTs (Falutz et al., NEJM 2010). Sermorelin's advantage is its longer track record as a compounded product in US clinical practice and a more pulsatile pharmacokinetic profile, though neither advantage is validated by head-to-head RCT data against the others in healthy adult populations.
Operational Guide: Reading Your Vial Label and COA
What to look for on the vial label:
- Total peptide mass (in mg or mcg) per vial
- Storage requirement (typically "refrigerate at 2 to 8 C before and after reconstitution")
- Beyond-use date (BUD) after reconstitution
- Pharmacy name, lot number, prescribing clinician name
- Route of administration (should say subcutaneous)
What to look for on the COA:
- Peptide identity: high-performance liquid chromatography (HPLC) purity percentage, ideally above 98%
- Potency: actual mcg per vial confirmed by UV or mass spectrometry, should match label claim within a narrow tolerance
- Sterility: USP 71 sterility test passed
- Endotoxin: bacterial endotoxins test (BET), limits per USP 85
- Residual solvents if applicable
A COA that only shows HPLC purity of the raw powder, without sterility or endotoxin testing on the finished vial, does not guarantee the final product is safe for injection. Ask your pharmacy specifically for the finished-product COA, not just the raw ingredient certificate.
Stability and the Degraded-Vial Problem
Sermorelin is a peptide, and peptides degrade through several pathways: hydrolysis of peptide bonds (accelerated by heat and extremes of pH), oxidation of susceptible residues (accelerated by light and dissolved oxygen), and aggregation. Bacteriostatic water (0.9% benzyl alcohol) is used for reconstitution specifically to inhibit microbial growth over the multi-dose period; it does not prevent chemical degradation of the peptide itself.
Temperature matters most. Storage above 8 C accelerates degradation substantially, though precise published half-life data for reconstituted compounded sermorelin at various temperatures are not available in the public literature. The practical rule from compounding standards is: refrigerate, do not freeze, protect from light, and use within the pharmacy-specified BUD (typically 30 days after reconstitution).
What a degraded vial looks like: Clear and colorless is correct. Cloudy, yellow, brown, or containing visible particles means discard. A vial that was accidentally frozen may appear clear but could have aggregated protein that is not visible; the clinical consequence of injecting aggregated peptide is uncertain but there is no reason to use a vial with a compromised cold chain.
Why this matters for your ml calculation: A partially degraded vial contains less active peptide than the label states. Even if you inject the arithmetically correct volume, you may be getting a sub-therapeutic dose if the peptide has broken down. This is a real-world limitation that peptide dosing guides rarely acknowledge.
FAQ
How many ml of sermorelin should I take?
The ml volume you inject depends entirely on how your vial was reconstituted. A common clinical starting dose is 200 to 300 mcg injected subcutaneously at night. If your vial contains 3 mg (3,000 mcg) reconstituted with 3 ml of bacteriostatic water, each 0.10 ml delivers 100 mcg, so a 300 mcg dose equals 0.30 ml. Always verify the math with your prescribing clinician before injecting.
What is the standard clinical dose of sermorelin in mcg?
Prescribers commonly start adults at 200 to 300 mcg per night subcutaneously and adjust based on IGF-1 response and tolerability. Some protocols go to 500 mcg nightly. The former FDA-approved Geref Diagnostic used 1 mcg/kg IV as a one-time diagnostic test, which is a different context from ongoing compounded therapy.
How do I calculate the ml volume from a reconstituted vial?
Divide your dose in mcg by the concentration in mcg/ml. Concentration equals total mcg in the vial divided by ml of bacteriostatic water added. Example: a 3,000 mcg vial plus 3 ml water equals 1,000 mcg/ml. A 300 mcg dose equals 0.30 ml, which is the 30-unit line on a U-100 insulin syringe.
What syringe should I use to draw sermorelin?
A U-100 insulin syringe (100 units per ml) is standard for subcutaneous peptide injections. Each unit mark equals 0.01 ml, giving precise measurement of small volumes. For a 0.30 ml dose, draw to the 30-unit line. Use a 28 to 31 gauge, 5/16-inch needle for subcutaneous injection.
Does injection timing affect how much sermorelin to take?
Timing affects efficacy, not the dose amount itself. Sermorelin is almost universally prescribed at bedtime to coincide with the natural growth hormone pulse. Injecting 30 to 60 minutes before sleep is the standard clinical recommendation. Food within 2 to 3 hours before injection may blunt the GH response by elevating insulin and glucose.
How long does a reconstituted sermorelin vial last?
Reconstituted sermorelin stored at 2 to 8 degrees Celsius is generally considered stable for up to 30 days per typical compounding pharmacy labeling. Peptide degradation is accelerated by heat, repeated freeze-thaw cycles, and light exposure. Discard if the solution becomes cloudy or contains particulate matter.
Can I take more sermorelin to see faster results?
Higher doses do not linearly increase GH output. Sermorelin acts on pituitary GHRH receptors, and receptor saturation combined with somatostatin feedback limits the ceiling effect. Supraphysiologic stimulation may paradoxically trigger more somatostatin-mediated negative feedback. Clinical titration based on IGF-1 labs is more reliable than simply increasing volume.
What does a degraded sermorelin vial look like?
Properly reconstituted sermorelin is a clear, colorless solution. Discard the vial if you see cloudiness, particulate matter, yellow or brown discoloration, or if the solution has been stored outside 2 to 8 degrees Celsius for more than a brief period. Do not inject degraded peptide.
Is sermorelin still FDA approved?
The original branded product Geref (Serono) was voluntarily withdrawn from the US market in 2008 for commercial reasons, not safety concerns. Sermorelin is currently available only as a compounded drug from licensed 503A or 503B pharmacies in the US, requiring a valid prescription. It is not an over-the-counter peptide.
How does sermorelin compare to tesamorelin or CJC-1295?
Sermorelin has the shortest half-life of the three (roughly 10 to 20 minutes), giving it the most physiologically pulsatile profile. Tesamorelin has an FDA-approved indication for HIV-associated lipodystrophy and stronger RCT evidence. CJC-1295 with DAC has a much longer half-life creating sustained GH elevation, which represents a different risk-benefit profile from pulsatile stimulation.
What injection site should I use for sermorelin?
Subcutaneous injection into the abdominal fat (at least 2 inches from the navel), outer thigh, or back of the upper arm is standard. Rotate sites to avoid lipohypertrophy. Pinch the skin, insert the needle at 45 to 90 degrees depending on tissue depth, and inject slowly over several seconds.
Sources
- Geref (sermorelin acetate) prescribing information, Serono Laboratories. Archived FDA label. Available via FDA Drugs@FDA database.
- Geref Diagnostic (sermorelin acetate) prescribing information, Serono. FDA NDA records (NDA 020011). Archived FDA label.
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2010;362(23):2141-2150. (Tesamorelin RCT cited for comparative evidence grading.)
- Thorner MO, et al. "Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging." Recent Progress in Hormone Research. 1997;52:215-244.
- USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. Current revision.
- USP General Chapter 85: Bacterial Endotoxins Test. United States Pharmacopeia.
- FDA. "Compounding and the FDA: Questions and Answers." US Food and Drug Administration. Updated guidance documents available at fda.gov.
- Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analogue, normalizes growth in the GHRH knockout mouse." American Journal of Physiology. 2006;291(6):E1290-E1294. (Cited for comparative GHRH analog pharmacokinetics.)
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308.
Research compound / compounded medication disclaimer: Sermorelin is a compounded prescription medication in the United States. It is not an FDA-approved drug for adult use and is not available over the counter. Access requires a valid prescription from a licensed prescriber and dispensing from a licensed 503A or 503B compounding pharmacy.
Results disclaimer: Individual responses to sermorelin vary. No outcome, including changes in IGF-1 levels, body composition, or subjective wellbeing, is guaranteed. The evidence base for sermorelin in healthy adults is limited and graded accordingly on this page.
Trademark disclaimer: Geref is a registered trademark of Serono. FormBlends has no affiliation with Serono or any pharmaceutical manufacturer. All trademarks are the property of their respective owners.